RESUMO
Heterogeneity in the load capacity of nodes is a common characteristic of many real-world networks that can dramatically affect their robustness to cascading overloads. However, most studies seeking to model cascading failures have ignored variations in nodal load capacity and functionality. The present study addresses this issue by extending the local load redistribution model to include heterogeneity in nodal load capacity and heterogeneity in the types of nodes employed in the network configuration and exploring how these variations affect network robustness. Theoretical and numerical analyses demonstrate that the extent of cascading failure is influenced by heterogeneity in nodal load capacity, while it is relatively insensitive to heterogeneity in nodal configuration. Moreover, the probability of cascading failure initiation at the critical state increases as the range of nodal load capacities increases. However, for large-scale networks with degree heterogeneity, a wide range of nodal load capacities can also suppress the spread of failure after its initiation. In addition, the analysis demonstrates that heterogeneity in nodal load capacity increases and decreases the extent of cascading failures in networks with sublinear and superlinear load distributions, respectively. These findings may provide some practical implications for controlling the spread of cascading failure.
RESUMO
RATIONALE: Due to the lack of specificity symptoms and site of onset of castleman disease (CD), it is difficult to diagnose and poses unique challenges for both patients and clinicians, leading to confusion in diagnosis and delays in treatment. To enhance understanding, we present 3 cases of CD treated at our hospital, including a single-center, multicenter, and mixed-type CD. PATIENT CONCERNS: Case 1: A 53-year-old female patient was admitted with a chief complaint of "abdominal pain and fever for 10 days." Marked enlargement of inguinal lymph nodes on both sides was observed. Case 2: A 58-year-old female patient was admitted with the main complaint of "discovering a left lower abdominal mass during a routine checkup for the past 10 days." Upon deep palpation, a palpable mass of approximately 5.0 * 3.0 cm was identified in the left lower abdomen. Case 3: A 40-year-old male patient was admitted with the main complaint of "progressive right upper abdominal and lumbar back pain for over 6 months." Computed tomography examination revealed multiple nodular soft tissue masses between the abdominal aorta and inferior vena cava, with the largest measuring 5.0 * 4.0 cm. DIAGNOSES: Based on the immunohistochemical results, the diagnoses for the 3 patients are as follows: Case 1: Multicentric Castleman's Disease (Mixed Type). Case 2: Pelvic Retroperitoneal Castleman Disease (Hyaline Vascular Type). Case 3: Castleman Disease Multicentric Type. INTERVENTION: Case 1: cyclophosphamide 0.6-1 gâ +â vincristine 2 mgâ +â methylprednisolone 50 mg/5 days. Cyclophosphamide 1 gâ +â prednisone 30-50 mg/5 days. This alternating chemotherapy cycle is repeated every 6 months. Case 2: Laparoscopic pelvic mass excision surgery. Case 3: Surgical excision of the mass. OUTCOMES: Case 1: After a 43-month follow-up, the patient's general symptoms have improved compared to before, but regular chemotherapy is still necessary at present. Case 2: The patient did not take any medication postoperatively, and there has been no evidence of metastasis or recurrence during the 18-month follow-up. Case 3: The patient did not take any medication, and there has been no evidence of metastasis or recurrence during the 21-month follow-up. LESSONS SUBSECTIONS: The lack of specific signs on imaging studies and nonspecific blood tests increases the difficulty of diagnosis. However, tissue biopsy remains a feasible option. Therefore, we recommend conducting thorough examinations for suspected CD patients to reduce misdiagnosis and determine the CD type for effective targeted treatment.